scispace - formally typeset
S

Silvano Sozzani

Researcher at Sapienza University of Rome

Publications -  352
Citations -  47443

Silvano Sozzani is an academic researcher from Sapienza University of Rome. The author has contributed to research in topics: Chemokine & Chemokine receptor. The author has an hindex of 98, co-authored 335 publications receiving 43598 citations. Previous affiliations of Silvano Sozzani include University of Turin & Brescia University.

Papers
More filters
Book ChapterDOI

Chemokines and Chemokine Receptors

TL;DR: Classic chemoattractants include complement components, formyl peptides and leukotriene B4, and various cytokines are able to elicit directional migration of leukocytes.
Book ChapterDOI

The Targeting of Leukocytes by 5-Oxo-Eicosanoids

TL;DR: A newly defined 5-HETE analog, 5-oxoETE, has in vitro actions suggesting that it could be such a mediator in vivo, and an eicosatetraenoate (ETE) may link Eo to allergy.
Journal ArticleDOI

Human Metapneumovirus Establishes Persistent Infection in Lung Microvascular Endothelial Cells and Primes a Th2-Skewed Immune Response

TL;DR: It is shown that HMPV productively infects human lung microvascular endothelial cells (L-HMVECs) and that HmpV, per se, could reproduce the ability of secretome to prime pro-Th2 DCs, suggesting that H MPV might take part in the development of a skewed, pro- Th2 lung microenvironment.
Journal ArticleDOI

The Chemerin/ChemR23 Axis Plays a Pivotal Role in the Pathogenesis of Intestinal Damage in a Murine Model of Graft Versus Host Disease

TL;DR: In this paper, the authors evaluated the potential role of Chemerin/ChemR23 axis in the pathogenesis of GvHD, in order to identify disease-specific pathways exploitable for developing new potential therapeutic targets.
Journal ArticleDOI

The PDE4 inhibitor tanimilast shows distinct immunomodulatory properties associated with a type 2 endotype and CD141 upregulation

TL;DR: Tanimilast is a selective inhaled inhibitor of phosphodiesterase-4 in advanced clinical development for chronic obstructive pulmonary disease (COPD), which is known to exert prominent anti-inflammatory activity when tested in preclinical experimental models as well as in human clinical studies as discussed by the authors .